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V-073, a small-molecule capsid inhibitor originally developed for nonpolio enterovirus indications is considerably more potent
against polioviruses. All poliovirus isolates tested to date (n 45), including wild, vaccine, vaccine-derived, and laboratory
strains, are susceptible to the antiviral capsid inhibitor V-073. We grew poliovirus in the presence of V-073 to allow for the iden-
tification of variants with reduced susceptibility to the drug. Sequence analysis of 160 independent resistant variants (80 isolates
of poliovirus type 1, 40 isolates each of types 2 and 3) established that V-073 resistance involved a single amino acid change in
either of two virus capsid proteins, VP1 (67 of 160 [42%]) or VP3 (93 of 160 [58%]). In resistant variants with a VP1 change, the
majority (53 of 67 [79%]) exhibited a substitution of isoleucine at position 194 (equivalent position 192 in type 3) with either
methionine or phenylalanine. Of those with a VP3 change, alanine at position 24 was replaced with valine in all variants (n
93). The resistance phenotype was relatively stable upon passage of viruses in cell culture in the absence of drug. Single-step
growth studies showed no substantial differences between drug-resistant variants and the virus stocks fromwhich they were
derived, while the resistant viruses were generally more thermally labile than the corresponding drug-susceptible parental vi-
ruses. These studies provide a foundation fromwhich to build a greater understanding of resistance to antiviral compound
V-073.
In 1988, the World Health Organization (WHO) launched theGlobal Polio Eradication Initiative (GPEI). The Initiative has
relied exclusively on the oral polio vaccine (OPV), an inexpensive
and easily administered live, attenuated vaccine. OPV is generally
safe and has been highly effective under most circumstances.
However, at a low frequency, about 1 per 750,000 vaccinees, OPV
itself can cause paralysis (vaccine-associated paralytic poliomyeli-
tis [VAPP]) (1).Normally, OPVviruses are excreted in the stool of
healthy vaccinated individuals for several weeks. Should these ex-
creted vaccine-related polioviruses continue to circulate (termed
circulating vaccine-derived polioviruses [cVDPVs]), virus rever-
sion to neurovirulence can occur and result in paralytic disease
and outbreaks. Moreover, when individuals with a primary im-
mune deficiency, such as agammaglobulinemia, receive OPV, the
virus may replicate persistently, accumulating genetic changes as-
sociated with reversion to neurovirulence. The resulting immu-
nodeficiency-associatedVDPVs can be excreted for years, posing a
risk of paralysis for the infected individual and compromising
efforts to eradicate the virus. As wild poliovirus transmission is
eliminated, and VAPP and VDPV cases continue to occur, the
risks of OPV use will outweigh its benefits. Thus, part of the GPEI
strategy involves the global cessation of OPV use when it is deter-
mined wild poliovirus transmission has ceased (2).
After reviewing current and post-OPV risks, the National Re-
search Council of the National Academies concluded that at least
one, preferably two, polio antiviral drugs be developed as a sup-
plement to the tools currently available for control of polio out-
breaks posteradication (4, 5).
V-073, a small-molecule capsid inhibitor originally developed
for nonpolio enterovirus indications (3), was recently found to be
considerably more potent against polioviruses (14). V-073 is cur-
rently being advanced for possible use in the management of po-
liovirus chronic infections and laboratory incidents. While V-073
is active against all poliovirus isolates tested to date (14), due to the
quasispecies nature of RNA viruses, there likely exist drug-resis-
tant variants at low levels in drug-susceptible virus populations.
Treatment-emergent drug resistance could potentially have med-
ical and public health implications. On the other hand, drug-re-
sistant virus variants may be enfeebled or otherwise more benign.
Thus, it is important to understand drug resistance and its poten-
tial consequences.
Here, we describe the selection and isolation of V-073-resistant
poliovirus variants in cell culture, the genetic basis for resistance,
and several features of the variants, including cell culture growth,
phenotypic stability in cell culture, and thermal stability of virion
infectivity. The antigenic, immunogenic, and pathogenic features
of V-073-resistant polioviruses are reported elsewhere (9).
MATERIALS AND METHODS
Viruses. Type 1 VDPV isolates 10235 (cVDPV-1 isolated from the Do-
minican Republic, GenBank accession no. AF405625) and 10224
(cVDPV-1 isolated from the United States), type 2 isolate 10230
(cVDPV-2 isolated from Egypt, GenBank accession no. AF448783), and
type 3 isolate 10805 (cVDPV-3 isolated from Iran, GenBank accession no.
EU684056) were obtained from the Centers for Disease Control and Pre-
vention (CDC) Polio and Picornavirus Laboratory collection and propa-
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gated on LLC-MK2 cells at 37°C (types 1 and 2) or 36°C (type 3) in min-
imal essential medium (MEM) with Earle’s salts (Invitrogen, Carlsbad,
CA), supplemented with 2% fetal bovine serum (FBS; Atlas Biologicals,
Fort Collins, CO, or Thermo Scientific, Lafayette, CO).
Plaque assays. LLC-MK2 monolayer cells were grown in six-well cell
culture plates and washed with MEM (Invitrogen, Grand Island, NY).
Tenfold serial dilutions of each virus were prepared in MEM, and 200 l
was inoculated into each well. After infection at room temperature for 45
to 60 min, 2.5 ml of overlay solution was added, consisting of 0.45%
agarose (SeaKem LE agarose; Lonza, Rockland, ME) in MEM with 2%
FBS. After the agar overlay had gelled, the plates were incubated at 36°C or
37°C, as described above, for 36 to 46 h. The overlay was removed, and the
cells were stained with a solution of 0.4% formaldehyde and 0.03% crystal
violet for 30 min. The plates were then washed once with water and al-
lowed to dry overnight. Plaques were counted, and virus titer was deter-
mined.
Selection of poliovirus variants with reduced susceptibility to
V-073. For each virus, 10 independent substrains were obtained by plaque
purification. The substrains were amplified in LLC-MK2 cells in MEM
with 2% FBS. For drug-resistant variant selection, serial dilutions of each
plaque-purified virus were inoculated into LLC-MK2 cells in six-well
plates and covered under agar overlay with either no drug, drug at a final
concentration of 10 times the median effective concentration (EC50) for
that particular virus (10EC50), or drug at 50 times the EC50 (50EC50).
Drug (V-073) was provided by ViroDefense, Inc. The susceptibility of
these strains to V-073 was reported recently (14). For each parental virus,
two plaques from each selection condition were selected and propagated
in LLC-MK2 cells under the selection condition. Drug resistance fre-
quency was calculated by dividing the titer of the surviving plaques in the
presence of 50 EC50 V-073 by the titer of parental plaque-purified virus
in the absence of drug.
Drug susceptibility assay. Susceptibility of parental and drug-resis-
tant variants to V-073 and determination of the EC50s were performed as
described previously (15). Briefly, drug and virus were combined with
LLC-MK2 cells in 96-well plates in a cross-titration format to ensure
reaching endpoints for both drug and virus titrations, with duplicate wells
for each drug-virus concentration. After 3 days of incubation at 37°C, the
plates were stained with crystal violet, washed three times with water, and
allowed to dry overnight. Viral cytopathic effect was measured by reading
the absorbance at 590 nm. EC50s were derived by analyzing dose-response
absorbance values by four-parameter curve fitting using Prism 5.04
(GraphPad Software, Inc., La Jolla, CA).
Identificationof aminoacid changes inV-073-resistant variants.Vi-
ral RNAwas extracted and purified by using the QiaAmp viral RNAmini-
kit (Qiagen, Inc., Valencia, CA). The VP3 and VP1 capsid genes were
amplified by reverse transcription-PCR. PCR products were sequenced
with the PCR primers and additional primers within each amplicon. The
sequences of PCR and sequencing primers used are available upon re-
quest. Sequences were assembled using Sequencher (version 4.8; Gene
CodesCorp., AnnArbor,MI) and analyzed using theWisconsin Sequence
Analysis Package, version 11.0 (Accelrys, San Diego, CA). The sequences
were submitted to the GenBank sequence database under accession num-
bers JN105289 to JN105295.
Stability of V-073-resistant phenotype. V-073-resistant viruses rep-
resenting the two predominant variant classes were subjected to 10 cycles
of passage in LLC-MK2 cell cultures in the absence of drug. Viruses were
initially inoculated onto 105 LLC-MK2 cells in 24-well plates at a multi-
plicity of infection (MOI) of 0.01 and then passaged every 3 days by inoc-
ulating 50 l of a 104 virus dilution onto 105 fresh LLC-MK2 cells in 0.5
ml of MEM supplemented with 2% FBS. At the tenth passage, the EC50 of
the virus populations was determined. The distribution of resistant and
susceptible viruses was also determined by plaque assay in the presence or
absence of V-073 at 10 the respective EC50s, as described above.
Single-step growth curves. Single-step growth of the parental and
drug-resistant variants was carried out in LLC-MK2 cell monolayers in
24-well plates. Cells were washed withMEM and infected at anMOI of 10
with the test virus in replicate plates. After the plates were incubated for 45
min at room temperature, the inoculum was removed, and the cells were
washed with MEM without serum, and then 0.5 ml of MEM supple-
mented with 2% FBS was added (in the absence of V-073), and the plates
were incubated at 37°C in an atmosphere of 5% CO2. At 0, 2, 4, 6, 8, and
10 h postinoculation, a plate was frozen at 70°C. Plates were freeze-
thawed three times, and the virus titers in the supernatants were deter-
mined by plaque assay in the absence of V-073.
Virion thermal stability. The kinetics of heat inactivation was mea-
sured by incubating variant and parental viruses at 46°C for 0, 5, 15, 30, or
60 min. The titers of the treated viruses were determined by plaque assay
in the absence of V-073. For each time point, stability at 46°C was ex-
pressed as a ratio relative to the titer of virus obtained at 0 min.
Poliovirus sequence analyses. VP1 and VP3 sequences of the drug-
resistant variants were compared to a database of sequences composed of
circulating wild and vaccine-derived polioviruses using a customized
search program implemented in MATLAB R2010a (The MathWorks,
Natick, MA).
Structural modeling. Protomer homology models representing each
parental VDPV strain were created using the SWISS-model server (http:
//swissmodel.expasy.org/) (17) using the template PDB coordinate file
1EAH as a reference. Point mutations for each subsequent protomer were
created using the “Mutator” plug-in associated with the Visual Molecular
Dynamics (VMD) software package (8). Custom parameter data for the
associated V-073 molecule and covalently bound myristic acid were ob-
tained using the SWISS-param server (http://swissparam.ch/) (18).
Each protomer was assembled into a pentamer configuration using
the biological assembly data contained in the 1EAH crystal structure
metadata file. Pentamers were then solvated using a TIP3 water model in
a cuboidal system with 12-Å padding on each axis and ionized with so-
dium and chloride ions at a concentration representing 0.154 M. Energy
minimization and molecular dynamics simulation for 1 nanosecond at
37°C and one atmosphere pressure, was performed using the Nanoscale
Molecular Dynamics (NAMD) software package (16) on an SGI Altrix
supercomputer housed at the Victorian Life Sciences Computation Ini-
tiative, Melbourne, Australia. Postsimulation pentamers were decon-
structed into five individual protomers and fit-aligned to the original
1EAH coordinates and a final average protomer structure obtained. Sim-
ulation data analysis and image generation was achieved using VMD.
RESULTS
Isolation of V-073-resistant poliovirus variants from suscepti-
ble virus populations. Previously, we showed that 45 distinct po-
liovirus isolates, includingwild, vaccine, vaccine-derived, and lab-
oratory strains of poliovirus, were all susceptible to the capsid
inhibitor V-073, with anMIC for 90%of isolates (MIC90) of 0.076
M(14).However, due to the quasispecies nature of RNA viruses,
there likely exist drug-resistant variants at low levels in drug-sus-
ceptible virus populations. Indeed, poliovirus variants with re-
duced susceptibility to V-073 were isolated from drug-susceptible
virus populations by virus growth in cell culture in the presence of
V-073. Ten independent wild-type (parental) virus plaques were
picked for each of four polioviruses, two VDPV type 1 isolates
(strains 10224 and 10235), one VDPV type 2 isolate (strain
10230), and one VDPV type 3 isolate (strain 10805). The plaques
were each amplified by a single passage in LLC-MK2 cells to allow
generation of a quasispecies population (“pool”) from which
drug-resistant variants could be selected. Viruses from each pa-
rental pool were propagated in LLC-MK2 cells in the absence or in
the presence of V-073 at either 10 or 50 the EC50 for the re-
spective parental virus. Surviving plaques were quantified and
their titers compared to that of their parental virus. Under these
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selection conditions, the frequency of V-073-resistant variants in
populations of the polioviruses defined by selection at 10 the
parental virus EC50 ranged from 3.20 to 42.7  10
5 (Table 1).
Similar frequencies were observed when selection was conducted
at 50 the EC50 (3.31 to 30.4 10
5).
Genetic basis of resistance. To determine the genetic basis of
V-073 resistance, two surviving plaques from each of the parental
pools (20 drug-resistant variants from each selection condition
[10 and 50 EC50] derived from each of four parental viruses),
160 variants in all, were isolated. Initially, the complete capsid
region of two drug-resistant variants from type 1, type 2, and type
3VDPVswere sequenced and compared to their respective paren-
tal virus sequence. Amino acid changes in the variants that corre-
lated with the resistance phenotype were restricted to capsid pro-
tein coding regions for VP3 and VP1. This is consistent with the
observation that VP3 and VP1 are the only proteins in contact
with the drug when bound to the virus (10). Therefore, we subse-
quently sequenced the VP3 and VP1 coding regions of all variants
and their parental virus.
For each independently selected resistant virus, a single amino
acid change relative to its parental virus sequence in either VP1 or
VP3 was associated with the resistant phenotype (Table 2). Two
amino acid positions were predominantly associated with drug
resistance and together represented 91% (146 of 160) of all resis-
tant variants. In VP1, the isoleucine at position 194 (equivalent
position 192 in type 3 polioviruses) was replaced by either a me-
thionine or phenylalanine in 53 of 160 (33%) of the resistant vari-
ants analyzed, with an apparent preference for phenylalanine (38
of 54 [70%]). In VP3, the alanine at position 24 was replaced
exclusively with valine in 93 of 160 (58%) of the resistant viruses.
Two minor resistant variants were also observed, each represent-
ing 4% (6 of 160) of the total viruses analyzed, one found exclu-
sively in the type 1 virus 10224, in which the isoleucine at VP1
position 183 was replaced with threonine, and the other, from the
type 3 virus 10805, inwhich the phenylalanine at VP1 position 237
(position 236 in type 3) was replaced with leucine. The amino acid
change at VP1 position 237 was also found in 6 out of 40 resistant
variants of another type 2 VDPV (data not shown). There ap-
peared to be no consistent amino acid substitution bias associated
with the two drug selection concentrations.
Stability of the resistance phenotype. For further character-
ization of viruses resistant to V-073, we focused on variants exhib-
iting the two predominant amino acid substitutions, VP1
I194M/F and VP3 A24V. One representative of each variant for
each of the three poliovirus serotypes (6 resistant variants in all),
togetherwith their respective drug-susceptible parents, were char-
acterized. The susceptibilities to V-073 of the parental viruses and
their resistant variants, expressed as EC50s, are provided in Table
3. The reduction in susceptibility of the variants relative to their
parents ranged from 38-fold to 556-fold. To ascertain the sta-
bility of the resistance phenotype, the six resistant variants were
cultured in the absence of V-073. After 10 passages in the absence
of drug selection pressure, the proportion of the virus population





Resistance frequency 105 (95% CI)a
Selection at 10 EC50 Selection at 50 EC50
VDPV-1 10224 0.069 30.4 (24.0–38.4) 5.61 (4.25–7.41)
VDPV-1 10235 0.018 3.20 (2.24–4.57) 3.31 (2.50–4.37)
VDPV-2 10230 0.036 26.5 (18.2–38.7) 11.8 (7.48–18.6)
VDPV-3 10805 0.029 42.7 (18.2–100) 30.8 (15.6–61.0)
a 95% CI, 95% confidence interval.
TABLE 2 Amino acid changes associated with resistance to V-073
Virus EC50




A, 88 P, 161 I, 183 I, 194b F, 237c A, 24
VDPV-1 10224 10 S (2) T (6) M (1) V (8) 20
F (3)
50 V (19) 20
T (1)d V (1)
VDPV-1 10235 10 F (9) V (11) 20
50 F (11) V (8) 20
M (1)
VDPV-2 10230 10 M (11) V (9) 20
50 M (2) V (18) 20
VDPV-3 10805 10 F (3) L (4) V (13) 20
50 F (12) L (2) V (6) 20
Totals 10 (%) 2 (2) 6 (8) 27 (34) 4 (5) 41 (51) 80
50 (%) 1 (1) 0 (0) 0 (0) 26 (32) 2 (2) 52 (65) 80
Total (%) 1 (1) 2 (1) 6 (4) 53 (33) 6 (4) 93 (58) 160
a Values for VP1 and VP3 are expressed as amino acidchanges (number of changes) except as noted for the totals in column 1. Columnsubheadings indicate the “wild amino acid,
residue number.”
b Equivalent residue 192 in type 3.
c Equivalent residue 236 in type 3.
d One virus had changes at both residues, VP188and VP324.
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that maintained the resistance phenotype was determined by
plaque assay in both the absence and presence of V-073 at 10 the
EC50 for the respective virus. As shown inTable 3, after 10 passages
in the absence of drug selection pressure, the percentage of the
virus population retaining the resistant phenotype ranged from
100% (strains 10230.8 and 10805.1) to 37% (strain 10805.5), sug-
gesting that the resistant phenotype was generally stable in cell
culture and not strongly selected against. The EC50s for theV-073-
resistant viruses in the passage-10 virus populations were deter-
mined and found to be largely the same as the passage 0 virus for
five of the six resistant viruses studied (Table 3). However, in the
strain 10230.8 passage-10 population, the EC50 was reduced from
10 M to 0.31 M, suggesting a recovery of drug susceptibility
when propagated in the absence of drug selection, but it was still
10-fold less susceptible than its parental virus.
Virus growth in cell culture. To assess the virological conse-
quences of drug resistance, studies were performed in which
the resistant variant viruses were compared to their respective
drug-susceptible parental virus population. In the first of these,
a single step growth curve in cell culture of the predominant
VP1 and VP3 variants in the absence of drug was conducted in
parallel with the respective parental virus. There appeared to be
no substantial difference in the single step growth curve pro-
files for any of the resistant variants relative to their respective
parental virus, using an MOI of 10 (Fig. 1). All variants repli-
cated to approximately the same peak titer and with approxi-
mately the same kinetics as their respective parental strain,
indicating there was no major deficit in viral replicative capac-
ity in cell culture. Similar results were also observed at MOI of
1 or 0.1 (data not shown).
Thermal stability of virus infectivity. It has been reported
previously that drug resistance to enterovirus capsid inhibitors
results is a more thermally labile virion (12). Thermolability is
thought to be due to the presence of bulkier amino acids in the
pocket, impacting the binding of natural factors that bind into the
pocket and stabilize the virion in the extracellular space. To inves-
tigate whether the changes necessary to confer V-073 resistance
affect virion stability, V-073-resistant variants were heated in cul-
ture medium without FBS at 46°C for various periods of time,
after which the surviving poliovirus infectivity was determined.
Four of the six resistant variants were substantially more heat la-
bile than their respective parental virus, while two variants
(10235.1 and 10230.4) showed only a slight reduction in thermal
stability (Fig. 2).
Structural modeling of drug-resistant variant viruses com-
plexedwithV-073.Tobetter understand themechanismofV-073
resistance, we modeled the amino acid changes responsible for
resistance in all three polio serotypes, based on the known crystal
structure of V-073 complexed with poliovirus type 2 (Fig. 3). The
isoleucine at VP1194 (192) and alanine at VP324 both have hydro-
phobic interactions with the dichlorophenyl portion of the drug.
The observed substitutions in VP1194 (192) and VP324 disrupt this
interaction and cause deformation of the drug-binding pocket.
The amino acid residues of the minor variants (Table 2) are also
predicted to impinge on the drug-binding pocket (data not
shown). The phenyl group of Phe236 residue in VP1 virus appears
to interact with the chloro-methoxyphenyl portion of the drug,
and this interaction is ablated in the type 3 virus with Leu substi-
tuted at residue 236.





EC50 (M) Passage 10




10235.1 VP1 I194F 10 10 82




10230.4 VP1 I194 M 1.5 3.0 43




10805.1 VP1 I192F 10 10 97
10805.5 VP3 A24V 1.1 1.0 37
a Passage was performed in the absence of drugselection.
b Resistance was determined at 10 the parental EC50.
c NA, not applicable.
FIG 1 Single-step growth curves. Cultures of LLC-MK2 cells were infected at an MOI of 10 with drug-susceptible parent virus and two drug-resistant variants
for each poliovirus type (types 1, 2, and 3) described in Table 3. The amount of infectious virus present at various times postinfection was quantified by plaque
assay. Solid circles, parental viruses; diamonds, VP1 I194 variants (VP1 I192 for type 3); triangles, VP3 A24 variants.
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The National Research Council of the National Academies has
recommended that at least one, preferably two, polio antiviral
drugs be developed as a supplement to the tools currently available
for control of polio outbreaks posteradication (4, 5). Pursuant to
this recommendation, poliovirus-specific capsid inhibitor V-073
is being advanced clinically to assess the potential utility of polio-
virus antiviral drugs in the treatment of chronic poliovirus infec-
FIG 2 Thermal inactivation of virus infectivity. Drug-susceptible parental virus and two drug-resistant variants for each poliovirus type (types 1, 2, and 3)
described in Table 3 were exposed to 46°C for various times, and the remaining infectivity determined by plaque assay. Solid circles, parental viruses; diamonds,
VP1 I194 variants (VP1 I192 for type 3); triangles, VP3 A24 variants.
FIG 3 Location in the poliovirus type 2 structure of predominant amino acids substitutions that confer resistance to V-073, based on the crystallographic
structure of V-073 bound to poliovirus type 2 (10). Superolateral cutaway view of electron density maps showing V073 bound within the hydrophobic pocket of
VP1. Density mapping at 1 Å resolution and 2 Å radius representing the original parental strain (cyan) with a wireframe overlay (yellow) of the resistant virus.
Amino acid differences are shown as a liquorice representation with parental (magenta) and variant (yellow). The final frame in the figure shows the position of
V073 (white) relative to the overall pentamer structure with VP1 (blue), VP2 (yellow), and VP3 (red); VP4 is not visible in this representation.
Liu et al.
5572 aac.asm.org Antimicrobial Agents and Chemotherapy
 o
n







tions and management of polio incidents. As with the application
of any antiviral drug, the issue of treatment-emergent drug resis-
tance presents a potential obstacle to implementation. It is impor-
tant to understand the potential for and consequences of antiviral
resistance.
We show here that poliovirus variants with reduced suscepti-
bility to V-073 can be isolated in cell culture from otherwise drug-
susceptible virus populations. The frequency of these variants in
virus populations was estimated at 3.20  105 to 42.7  105
(geometric mean, 16.8 105). The frequency of drug resistance
observed with V-073 is similar to that reported for other capsid
inhibitors. For example, the frequency of HRV14 resistance to
WIN 52084 was about 4 105 (7), and that of coxsackievirus B3
to pleconaril was 5 105 (6).
It was reported previously that poliovirus type 3 variants se-
lected for resistance to capsid inhibitorsmay also be dependent on
drug for their growth (11–13). Drug dependence is characterized
by plating indices (ratio of the plaque titer in the presence of drug
to the plaque titer in the absence of drug) of about 400 to2,000,
while nondependent drug-resistant variants have values close to 1
(i.e., similar plaque titers with or without drug) (11). The variants
studied here had plating indices that ranged from 0.42 to 1.24,
indicating a lack of drug dependence. It is unclear why we did not
observe drug-dependent viruses in our study; however, it has been
reported that the frequency of such viruses may vary widely
among different enteroviruses (11). Of course, the physicochem-
ical properties of the drug compound may also influence the type
of variants detected and V-073 is chemically distinct from the
compounds used to select drug-dependent variants, despite their
common mechanism of action.
As described previously for other picornavirus capsid inhibi-
tors, the basis for resistance lies in single amino acid substitutions
involving residues that line the drug-binding pocket (6, 7, 12).
Here, sequence analysis of 160 independent resistant variants (80
isolates of poliovirus type 1, 40 isolates each of types 2 and 3)
established that V-073 resistance also involved single amino acid
changes, predominantly at two sites, at isoleucine residue 194 in
VP1 (192 in poliovirus type 3) or in VP3 at alanine 24.Minor sites
where an amino acid change conferred resistance include pro-
line161, isoleucine183, and phenylalanine236, all in VP1. The loca-
tions of the amino acid substitutions are consistent with those
observed in polioviruses and rhinoviruses that are resistant to
other capsid-binding antiviral compounds (7, 12). For example,
the I1192F change confers resistance to WIN 51711 in PV3 (12)
and V1188M, lying in a similar position in human rhinovirus 14,
confers resistance to the related compound, WIN 52084 (7).
The resistant viruses studied in this report were derived in the
laboratory from drug-susceptible virus populations by selection
in cell culture. When a collection of naturally occurring poliovi-
ruses, including wild polioviruses and VDPVs, were tested for
V-073 susceptibility, all of the 42 polioviruses were susceptible,
with EC50s ranging from 0.003 to 0.126M (14). In that study, all
polioviruses possessed the drug-susceptible genotype encoding
isoleucine at residue 194 (192 in type 3) in VP1 and alanine at
residue 24 in VP3. When the CDC database of 4,500 VP1 se-
quences and 250 VP3 sequences, representing all known poliovi-
rus genotypes, including sequences for recently circulating lin-
eages, was inspected, there was an absolute conservation of these
two residues. Thus, while we are able to select for and isolate
V-073-resistant variants from drug susceptible virus stocks in the
laboratory, the above observations suggest that changes at these
positions are rare in nature.
Our initial cell culture investigations into the stability and fit-
ness of V-073-resistant variants presented here revealed mixed
results. Single cycle cell culture growth of resistant variants was
indistinguishable from that of their corresponding parental vi-
ruses, an observation described previously for other picornavirus
capsid inhibitors (6, 11). Furthermore, the drug resistance pheno-
type appeared relatively stable upon cell culture passage of the
resistant viruses studied; however, one of the six variants studied
appeared to reacquire some level of drug susceptibility. Finally,
the thermal stability data suggested generally reduced virion sta-
bility of the resistant viruses compared to their susceptible par-
ents, a feature previously noted for picornavirus capsid inhibitor
resistance (6, 11).
To explain the lack of drug-resistant viruses among a broad
panel of poliovirus isolates, as well as the lack of genotypic repre-
sentation in the database, additional assessments of V-073 resis-
tance are necessary. Itmay be that the parameters of cell culture do
not reflect fitness penalties that would be associated with resis-
tance to V-073 in infections in a living host. Indeed, when evalu-
ated in mice, we found that laboratory-derived V-073-resistant
variants exhibit clear attenuation of their replicative capacity and
neurovirulence (9). Further study ofV-073 resistance, particularly
in the context of treatment-emergent resistance in clinical studies
with V-073, is warranted.
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